Synchronization of the availability of good quality oocytes from donors and adequate endometrial maturation of recipients are very important for the success of an oocyte donation programme. A flexible protocol for the endometrial preparation of recipients is important in timing embryo transfer between days 17 and 19 of the cycle ('window of receptivity'). The purpose of this study was to evaluate the effect of the length of oestradiol administration to recipients on pregnancy outcome. Oestrogen administration was 8 mg/day, but its length varied prospectively from 6 to 27 days, followed by the addition of progesterone (100 mg daily Lm.) for 2-4 days according to the availability of good quality oocytes. Pregnancy outcome was evaluated regardless of age, indication for oocyte donation or number of embryos transferred per patient The pregnancy rate per cycle was comparable when oestradiol was administered from 6 to 11 days before progesterone addition, while it dropped significantly thereafter. The variation in progesterone administration did not affect pregnancy outcome. These findings provide us with a greater flexibility by allowing us to vary oestradiol administration to recipients from 6 to 11 days prior to progesterone, reducing considerably, therefore, the need to cancel embryo transfer because of oocyte unavailability. Thus we can arrange to transfer embryos between days 17 and 19 of the recipient's cycle so as to obtain the best possible clinical outcome.
Introduction
Oocyte donation, a treatment similar to artificial insemination by donor for male infertility, has extended the potential of assisted reproduction for infertile couples (Bustillo et al., 1984; Lutjen et al, 1984; Edwards et al, 1991) . Ovarian failure, multiple previous failures of conception in an in-vitro fertilization (TVF) and embryo transfer programme or genetic disease are the major indications for entering such a programme. Advanced age (patient's age >40 years) is an additional indication because pregnancy rates for aged patients undergoing © European Society for Human Reproduction and Embryology IVF and embryo transfer (Edwards et al, 1984) are considerably lower when compared with those with oocyte donation Paulson, 1992, 1993) .
Various hormone replacement therapies have been employed to prepare the recipient endometrium, which seems to be a major factor for successful outcome (Navot et al, 1991) . At first, a sequential steroid replacement therapy was used to simulate the natural menstrual cycle (Lutjen et al, 1984; Rosenwaks, 1987; Leeton et al., 1991; Bustillo et al, 1995) , followed by protocols consisting of a fixed dose of oestradiol and progesterone (Serhal and Craft, 1987; Ben-Nun et al, 1989; Leeton et al, 1991; Zegers-Hochschild et al, 1992) . Constant regime protocols using a different dose of oestradiol have also been employed (Leeton et al, 1991; Zegers-Hochschild et al, 1992) .
The purpose of this study was to investigate whether the length of oestrogen administration prior to the addition of progesterone was an influential factor in the outcome of an oocyte donation programme that provided recipients with the constant daily administration of oestradiol and progesterone. A variable length of oestrogen administration with good clinical outcome would allow us a greater flexibility in synchronizing recipient and donor cycles so as to arrange the transfer of embryos between days 17 and 19 of the recipient's artificial cycle. This period has been shown to be the most appropriate 'window of receptivity' of the endometrium (Rosenwaks, 1987; Navot and Rosenwaks, 1990; Martel et al, 1991; Navot etal, 1991) .
Materials and methods
A total of 117 women were included in this study (from 1992 to 1994) . Indications for entering the programme (Devroey et al., 1989; Abdalla et aL, 1990; Psychoyos, 1993) were (i) elevated serum follicle stimulating hormone (FSH) concentrations (FSH 5» 14 mlU/ ml), (ii) advanced age (5*39 years old) with normal serum FSH concentrations, or (iii) multiple failures to conceive (more than three) in an IVF and embryo transfer programme. Their mean age was 39.2 years (range 25-48). All recipients were subjected to a careful precycle medical screening to prevent the inclusion of patients with known pre-existing diseases (especially cardiovascular and diabetic; Beckett and Serhal, 1994) .
In our programme, we used excess oocytes from IVF and embryo transfer cycles that were voluntarily donated by the patients after informed consent. Anonymity of the recipients and donors was strictly maintained. All donors were <34 years old and were screened for hepatitis B and C, human immunodeficiency viruses I and II, syphilis, chlamydiae and vaginal infections. A detailed history was obtained to exclude potential carriers of genetic disease.
Ovulation in the donors was induced by gonadotrophin-releasing hormone analogues and gonadotrophins (Remohi et al., 1994 Follicular aspiration and oocyte retrieval were performed by transvaginal ultrasonographically guided puncture 34-36 h after HCG administration. The oocytes were cultured in Ham's F-10 medium without hypoxanthine and with 4% bovine serum albumin, as described previously (Kiessling el al., 1988) . Since the potential donors were IVF patients themselves, only those who yielded more than six oocytes were considered as donors. Their excess oocytes were then donated to the matched recipients.
Recipients were given 2 mg oestradiol valerate per os (Cyclacur, Schering, Berlin, Germany) four times daily, followed by the daily addition of 100 mg progesterone in oil (Lutorm; Chropi, Athens, Greece) i.m. (Nikas et al, 1995) . Patients were prospectively followed using a protocol which allowed for oestradiol administration between 6 and 27 days prior to the addition of progesterone. Menstruating patients started receiving oestradiol on day 2 of their cycle, hi amenorrhoeic patients, oestradiol administration was started arbitrarily. Recipients were synchronized with donors so that the day on which oocytes were retrieved, the recipient started progesterone treatment. The first day of progesterone administration was considered as 'day 15' of the artificial cycle, irrespective of the day of oestradiol administration. Concepti were then transferred to the recipients on the third (day 17), fourth (day 18) or fifth (day 19) day after progesterone administration, depending on the availability of good quality oocytes and, eventually, embryos. All embryos transferred were day 2 embryos. The mean number of cells per embryo was 4.7 ± 2.0 for day 3, 3.8 ± 1.3 for day 4 and 4.9 ± 1.9 for day 5. In most cases, three (n = 73) or four embryos (n = 70) were transferred to the uterus of the recipient, although two (n = 11), five (n = 6) or six embryos (n = 5) were also transferred. All embryos were fresh; there was no transfer of frozen-thawed embryos.
The luteal phase of the recipients was supported by oestradiol valerate per os and progesterone i.m. (same scheme as before transfer). If a pregnancy occurred, hormonal administration was continued until week 14 of pregnancy.
Statistics
Results were analysed by a one-way analysis of variance, the z-test for proportions or the % 2 te st, as noted in the tables.
Results
A total of 165 cycles of oocyte donation from 117 women were studied; 74 cycles were from patients with serum FSH concentrations 2«14 mlU/ml (mean serum FSH concentration 25.5 mlU/ml; mean age of patients 39.3 years), 55 cycles were from women of advanced age (mean age 41.2 years, range 39-48; serum FSH concentration =£14 mlU/ml) and 36 cycles were from patients who had already had at least three previous failures for conception in an IVF and embryo transfer programme (mean age 36.0 years; serum FSH concentration =sl4mIU/ml). 'Number of gestational sacs with a fetal heart beat by ultrasound divided by the number of embryos transferred (X100). b Number of multiple clinical pregnancies divided by the total number of clinical pregnancies (X100).
•^Number of abortions divided by the number of clinical pregnancies (X100).
The results of oocyte donation for the patients in our study are shown in Table I . A total of 581 embryos were transferred, resulting in 101 viable gestational sacs (with fetal heart beat discerned by ultrasound). The implantation rate was 17.4%. There were 57 clinical pregnancies, giving a pregnancy rate of 34.5% per cycle, hi all, 43 patients delivered (live birth rate per cycle 26.1%), and 10 of those gave birth to twins (17.5%). The total number of babies born was 53, while the abortion rate was 24.5%. The outcome of the pregnancies is shown in Table I .
The pregnancy rate per cycle according to the number of days of oestradiol administration prior to the addition of progesterone (artificial follicular phase) is shown in Table  II . Pregnancy rates were comparable when oestradiol was administered for a period varying from 6 to 11 days before the addition of progesterone, but they dropped thereafter. When taken separately for each period (6 days, 7 days, etc.), the number of patients was small for statistical comparisons; when all the patients for whom oestradiol was administered from 6 to 11 days were grouped and compared with those for whom oestradiol was given for a longer period, the former had a significantly higher pregnancy rate (47.9 versus 24.5%; P < 0.001; Table DT ).
In the majority of cycles (135 cycles), embryo transfer was performed on day 4 after progesterone administration (day 18); in 23 cycles the transfer was performed on day 3 (day 17) and in seven on day 5 (day 19). As is shown in Table IV , pregnancy rates were similar regardless of the length of progesterone administration (P > 0.05). Therefore this variation did not affect the pregnancy outcome.
The effect of progesterone administration was also studied separately for those patients who received oestradiol from 6 to 11 days (higher pregnancy rates) and for those who received oestradiol from 12 to 27 days (lower pregnancy rates). As shown in Table V , the length of progesterone administration had no effect on the outcome for either group, or for the total number of patients (P > 0.05 between all values of the first, second or third column of the table; one-way analysis of •Oestradiol administered for 6-11 days before progesterone addition. b Oestradiol administered for 12-27 days before progesterone addition. Irrespective of the number of days of oestradiol administration before the addition of progesterone.
•fenbryo transfer on day 3, 4 or 5 after progesterone administration. Trrespective of the number of days of progesterone administration. f P > 0.05 (not significant) between all four values of the first, second or third column (one-way analysis of variance); P < 0.001 between • and *• (ztest for proportions).
variance). The important parameter that affected the results significantly was the length of oestradiol administration prior to the addition of progesterone (artificial follicular phase). This was true for the total number of patients (P < 0.001; as shown in Tables m and V) , as well as for those that received progesterone for 4 days (F < 0.001; Table V) , who were the majority of the patients. For those who received progesterone for 3 or 5 days, although oestradiol administration affected the outcome, this effect was not statistically significant because of the small number of patients (Table V) .
Discussion
The results of this study show first of all that simulation of the physiological variation of hormonal concentrations during the menstrual cycle is not necessary for the induction of endometrial receptivity. A constant regimen of oestradiol valerate (2 mg four times daily per os), along with the addition of a constant i.m. administration of progesterone in oil (100 mg daily) resulted in high implantation and pregnancy rates (Table I ; Sauer and Paulson, 1992) .
For all patients, the proper preparation of the endometrium to receive the fertilized oocyte was a major factor in obtaining a pregnancy. The aforementioned protocol of hormone replacement therapy has been used by other groups with high pregnancy rates (Serhal and Craft, 1987; Zegers-Hochschild et al., 1992) , but for a limited number of recipients. When a smaller dose of oestradiol valerate was used (2 mg/day), lower pregnancy rates were reported (Leeton et al., 1991) .
The important finding of this study was the fact that oestradiol administration to recipients from 6 to 11 days gave comparably high pregnancy rates, which dropped significantly thereafter (Tables II and ITJ) . When excess oocytes from IVF are employed for donation, it is important to be able to synchronize recipient and donor cycles so that embryo transfer can be performed between days 17 and 19 of the recipient cycle, considering day 15 the first day of progesterone administration. This period has been shown to be the most appropriate for embryo transfers (Rosenwaks, 1987; Navot and Rosenwaks, 1990; Martel et al., 1991; Navot et al., 1991) . If the duration of oestradiol administration to recipients can be varied for a period of 6 days, one can take advantage of a larger number and a better quality of excess oocytes. The prolongation of oestrogen administration for > 11 days decreases significantly the chances of a recipient becoming pregnant.
Previous reports using micronized 17(i-oestradiol for endometrial preparation showed an optimal length of the artificial follicular phase between 12 and 19 days, with a sharp drop in pregnancy rate before or after this period (Younis et al, 1992) . Our results showed an optimal duration of oestradiol administration of 6-11 days prior to the addition of progester-one. Variations in absorption between 17{J-oestradiol and oestradiol valerate may be responsible for the differences in endometrial receptivity. These differences are caused by endometrial changes at the microscopic level, resulting in a functional deficiency of the endometrium (Manners, 1990) at different chronological periods after the initiation of oestrogen administration.
This study has also shown that the duration of progesterone administration does not affect the outcome, providing it lies between 2 and 4 days (Tables IV and V) . This therefore provides us with a 3 day time period within which good quality embryos may be available for transfer into the uterus of the recipient
In conclusion, endometrial receptivity can be induced successfully in recipients by employing a constant administration of oestradiol valerate per os and progesterone in oil i.m. The effectiveness of this regimen is strongly correlated to the duration of the artificial follicular phase, with best results between 6 and 11 days. Progesterone administration can also vary from 2 to 4 days, with no adverse effects on pregnancy rate. Thus we are provided with a greater flexibility for the synchronization of recipient to donor cycles when excess oocytes are used for donation by varying the oestrogen administration to recipients from 6 to 11 days prior to the addition of progesterone. Cancellation of the embryo transfer to recipients because of oocyte (and, therefore, embryo) unavailability is thus considerably reduced and embryo transfer can be arranged to take place between days 17 and 19 of the recipient's cycle so as to obtain the best possible clinical outcome.
